Phospho-Ets1 (Thr38) Antibody

What is Phospho-Ets1 (Thr38) Antibody and what is its specificity?

Phospho-Ets1 (Thr38) Antibody is a specialized research reagent designed to detect endogenous levels of the ETS1 transcription factor exclusively when phosphorylated at threonine 38. This antibody typically comes as a rabbit polyclonal antibody generated using synthetic phosphopeptides derived from human ETS1 around the phosphorylation site of Thr38 (amino acids 11-60) . The specificity of these antibodies is critical - they recognize the phosphorylated form without cross-reactivity to the non-phosphorylated ETS1 protein. Some commercial preparations ensure specificity by removing non-phospho-specific antibodies through chromatography using non-phosphopeptides .

What are the primary applications and optimal conditions for using Phospho-Ets1 (Thr38) Antibody?

Phospho-Ets1 (Thr38) Antibody can be utilized across multiple experimental platforms with different optimal dilutions:

The antibody is typically formulated in phosphate buffered saline (pH 7.4) with 150mM NaCl, 0.02% sodium azide, and 50% glycerol for stability . Researchers should store the antibody at -20°C and avoid repeated freeze-thaw cycles to maintain its activity.

How does phosphorylation at Thr38 impact ETS1 function biologically?

Phosphorylation at Thr38 serves as a critical marker for ETS1 activation and significantly alters its functional properties:

• Structural changes: Phosphorylation shifts a conformational equilibrium in ETS1, displacing the dynamic helix H0 from the core bundle of the PNT domain .

• Enhanced coactivator binding: The affinity of ETS1 for the TAZ1 (CH1) domain of the coactivator CBP is enhanced 34-fold upon phosphorylation .

• Transcriptional activation: Phosphorylated ETS1 exhibits increased capacity to regulate downstream target genes involved in cellular proliferation, differentiation, and survival .

• Signaling integration: This phosphorylation represents a "phospho-switch" that translates Ras/MAPK signaling into changes in gene expression patterns .

The dynamic helical elements of ETS1, when phosphorylated, constitute a mechanism for directing upstream signaling to downstream transcriptional outcomes. This post-translational modification is therefore central to understanding ETS1's role in both normal physiology and disease states.

What is the relationship between ETS1 phosphorylation at Thr38 and diffuse large B cell lymphoma (DLBCL)?

ETS1 phosphorylation at Thr38 exhibits a striking association with DLBCL subtypes, with important implications for disease biology:

• Subtype-specific expression: Phosphorylated ETS1 (p-ETS1) is detected in activated B cell-like DLBCL (ABC) but not in germinal centre B-cell-like DLBCL (GCB) cell lines .

• Clinical correlation: This pattern is mirrored in patient diagnostic biopsies, with p-ETS1 being significantly more common in ABC than GCB DLBCL samples .

• Growth regulation: Genetic inhibition of ETS1 phosphorylation at Thr38 impairs the growth of DLBCL cell lines .

• Transcriptome effects: Blocking ETS1 phosphorylation alters the BCR-mediated transcriptome program in DLBCL cells .

These findings suggest that ETS1 phosphorylation represents a potential therapeutic target in ABC-DLBCL. The research indicates that pharmacological inhibition of this pathway could benefit lymphoma patients by targeting a subtype-specific vulnerability .

What signaling pathways regulate ETS1 phosphorylation at Thr38?

ETS1 phosphorylation at Thr38 is primarily regulated by the MEK/ERK signaling axis:

• ERK2 phosphorylation: ERK2, a key effector of Ras/MAPK signaling, directly phosphorylates ETS1 at Thr38 and an additional site at Ser41 .

• MEK dependency: MEK inhibition significantly decreases both baseline and IgM stimulation-induced p-ETS1 levels in cell models .

• Kinetic parameters: The phosphorylation reaction involves a partially rate-limiting product release step (k_off = 59 ± 6 s^-1), with phosphorylated ETS1 binding >20-fold more tightly to ERK2 than ADP (K_d = 7.3 and 165 μM respectively) .

• Upstream activators: B-cell receptor (BCR) signaling can trigger this phosphorylation cascade in B-cell lymphomas .

This mechanistic understanding provides insight into how aberrant activation of the Ras/MAPK pathway in cancer can lead to altered ETS1 activity, contributing to disease pathogenesis.

How does the structure of ETS1 change upon phosphorylation at Thr38?

Phosphorylation at Thr38 induces significant conformational changes in ETS1 that have been characterized by sophisticated biophysical methods:

• Domain architecture: NMR spectroscopic analyses revealed that the PNT domain of ETS1 consists of a four-helix bundle (H2–H5) resembling the SAM domain, with two additional helices (H0–H1) .

• Conformational shift: Phosphorylation at Thr38 displaces the dynamic helix H0 from the core bundle, creating a structural reorganization .

• Interaction surfaces: NMR-monitored titration experiments mapped the interaction surfaces of the TAZ1 domain and ETS1, showing that both the phosphoacceptors and the PNT domain participate in binding .

• Electrostatic mechanism: Charge complementarity of these surfaces indicates that electrostatic forces work together with the conformational equilibrium to mediate phosphorylation effects .

This detailed structural information provides a foundation for understanding how phosphorylation at a single residue can have profound effects on protein function and potentially guides strategies for targeting ETS1 in human disease.

What technical considerations should researchers address when validating Phospho-Ets1 (Thr38) Antibody specificity?

Rigorous validation of Phospho-Ets1 (Thr38) Antibody specificity requires multiple complementary approaches:

• Phosphatase treatment control: Samples should be treated with lambda phosphatase to confirm loss of signal when phosphorylation is removed.

• Genetic models: Using ETS1 knockdown/knockout cells or tissues as negative controls.

• Phosphosite mutants: Creating T38A (non-phosphorylatable) or T38E/D (phosphomimetic) mutants to validate antibody specificity.

• Peptide competition assays: Pre-incubating antibody with the immunizing phosphopeptide should abolish specific binding.

• Signal induction: Confirming increased phosphorylation signal after stimulating the MEK/ERK pathway with appropriate agonists.

• Cross-reactivity assessment: Testing against related ETS family proteins to ensure specificity for ETS1.

• Appropriate controls: Including isotype controls (e.g., normal rabbit IgG) and phosphorylation-negative samples in all experiments.

Commercial antibodies often undergo purification by affinity-chromatography using epitope-specific phosphopeptides, with non-phospho specific antibodies removed by chromatography using non-phosphopeptides . These validation steps are essential for obtaining reliable and reproducible results.

What specialized assays and methodologies are available for studying ETS1 phosphorylation?

Several specialized methodologies have been developed for analyzing ETS1 phosphorylation:

• Cell-Based ELISA Kits: These kits allow for detection of ETS1 phosphorylation in intact cells and include multiple normalization methods:

  • Anti-GAPDH antibody as internal control

  • Crystal Violet whole-cell staining for cell density normalization

  • Total ETS1 antibody for normalizing to total protein levels

• Transcription Factor Activity Assays: These measure the functional activity of phosphorylated ETS1 as a transcription factor, providing information beyond mere presence of the modification .

• Kinetic Analysis Methods:

  • Isothermal titration calorimetry (ITC) for measuring binding affinities

  • NMR spectroscopy for structural analysis

  • Stopped-flow fluorescence for measuring binding kinetics

• In Vivo Models: Genetic approaches using phosphorylation-deficient mutants (T38A) or phosphomimetic mutants (T38E) to study functional consequences in cellular and animal models .

These methods provide researchers with a comprehensive toolkit for investigating ETS1 phosphorylation in diverse experimental contexts.

How do researchers experimentally manipulate ETS1 phosphorylation for functional studies?

Researchers employ several strategies to manipulate ETS1 phosphorylation for functional studies:

• Pharmacological approaches:

  • MEK inhibitors to decrease ERK-mediated phosphorylation

  • ERK inhibitors to directly block the kinase responsible for phosphorylation

  • Phosphatase inhibitors to enhance phosphorylation levels

• Genetic approaches:

  • Site-directed mutagenesis creating T38A (non-phosphorylatable) mutants

  • Phosphomimetic mutations (T38E or T38D) to simulate constitutive phosphorylation

  • siRNA/shRNA knockdown of ETS1 with rescue using wild-type or mutant variants

• Cellular stimulation:

  • IgM treatment to activate B-cell receptor signaling and induce phosphorylation

  • Growth factor stimulation to activate Ras/MAPK pathway

• CRISPR/Cas9 genome editing:

  • Generation of cell lines or animal models with modified ETS1 phosphorylation sites

When implementing these approaches, researchers should include appropriate controls and consider the potential for compensatory mechanisms or off-target effects.

What is the broader significance of ETS1 phosphorylation at Thr38 beyond lymphoid malignancies?

ETS1 phosphorylation at Thr38 has significant implications beyond lymphoid malignancies:

• Pancreatic β-cell function: ETS1 phosphorylation negatively regulates insulin secretion and β-cell function through upregulation of thioredoxin-interacting protein (TXNIP) .

• Drug resistance mechanisms: Phosphorylation of ETS1 at Thr38 is associated with osimertinib resistance, and compounds like xanthohumol can overcome this resistance by regulating ETS1 phosphorylation .

• Transcriptional networks: Phosphorylated ETS1 regulates various pathways including BCR signaling, CD40 signaling, NFκB/TNFα pathways, and immune responses .

• Cell differentiation: ETS1 phosphorylation status affects cellular differentiation programs in multiple lineages, including both lymphoid and non-lymphoid tissues.

• Cancer progression: As a transcription factor downstream of the Ras/MAPK pathway (often dysregulated in cancer), phosphorylated ETS1 contributes to oncogenic processes in multiple tumor types.

These diverse roles highlight the importance of ETS1 phosphorylation as a regulatory mechanism across multiple physiological and pathological contexts.

What therapeutic strategies targeting ETS1 phosphorylation are being developed?

Several therapeutic approaches targeting ETS1 phosphorylation are under investigation:

• Indirect targeting through upstream inhibitors:

  • MEK inhibitors that decrease ETS1 phosphorylation as part of their mechanism

  • ERK inhibitors that directly prevent phosphorylation of ETS1

• Direct ETS1 inhibitors:

  • TK-216: An inhibitor of ETS1 that shows efficacy in preclinical models with potentially reduced off-target effects compared to earlier compounds

  • YK-4-279: Shows strong anti-tumor activity in preclinical models but may have toxicity limitations

• Natural compounds:

  • Xanthohumol: Shown to overcome drug resistance by regulating ETS1 phosphorylation

• Combination therapies:

  • Targeting ETS1 phosphorylation alongside other pathways relevant to specific cancer types

• Structure-based drug design:

  • Utilizing the detailed structural information about the "phospho-switch" mechanism to design specific inhibitors

The development of these therapies is facilitated by the growing understanding of how ETS1 phosphorylation contributes to disease pathogenesis, particularly in lymphomas and other cancers.

How should researchers interpret discrepancies in Phospho-Ets1 (Thr38) detection across different assays?

When researchers encounter discrepancies in Phospho-Ets1 (Thr38) detection across different assays, they should consider several methodological factors:

• Antibody selection issues:

  • Different epitope recognition regions (some antibodies target 11-60 aa region while others may have more focused epitopes)

  • Clonal variation in polyclonal antibody preparations

  • Batch-to-batch variability

• Technical considerations:

  • Sample preparation methods that may dephosphorylate ETS1 during processing

  • Buffer conditions that affect antibody binding (particularly ionic strength, as phospho-ETS1 interactions are sensitive to this parameter)

  • Fixation protocols for IHC/IF that might mask the phospho-epitope

• Biological factors:

  • Rapid turnover of phosphorylation in cell systems

  • Context-dependent phosphorylation levels (cell type, activation state)

  • Presence of other post-translational modifications that may interfere with antibody binding

• Quantification approaches:

  • Different normalization methods used in cell-based assays

  • Threshold settings for positive/negative determination

Researchers should validate findings using multiple complementary techniques (Western blot, IHC, IF, ELISA) and include appropriate positive and negative controls to resolve discrepancies.